{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T15:52:58Z","timestamp":1792252378368,"version":"4.4.0"},"reference-count":36,"publisher":"e-Century Publishing Corporation","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Cancer Res"],"DOI":"10.62347\/vzzv6163","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T03:00:12Z","timestamp":1735614012000},"page":"5897-5908","source":"Crossref","is-referenced-by-count":3,"title":["Safety and infection risk factors in elderly acute myeloid leukemia patients undergoing induction therapy with venetoclax combined with hypomethylating agents"],"prefix":"10.62347","volume":"14","author":[{"given":"Wenshan","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"48694","published-online":{"date-parts":[[2024]]},"reference":[{"key":"ref0","unstructured":"Tang FF and Huang XJ. Treatment strategies of acute myeloid leukemia in elderly patients. Zhonghua Nei Ke Za Zhi 2023; 62: 324-328."},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Tang K, Schuh AC and Yee KW. 3+7 combined chemotherapy for acute myeloid leukemia: is it time to say goodbye? Curr Oncol Rep 2021; 23: 120.","DOI":"10.1007\/s11912-021-01108-9"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.annonc.2020.02.018","article-title":"Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Heuser","year":"2020","unstructured":"Heuser M, Ofran Y, Boissel N, Brunet Mauri S, Craddock C, Janssen J, Wierzbowska A and Buske C; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020; 31: 697-712.","journal-title":"Ann Oncol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","article-title":"Acute myeloid leukemia: current progress and future directions","volume":"11","author":"Kantarjian","year":"2021","unstructured":"Kantarjian H, Kadia T, DiNardo C, Daver N, Borthakur G, Jabbour E, Garcia-Manero G, Konopleva M and Ravandi F. Acute myeloid leukemia: current progress and future directions. Blood Cancer J 2021; 11: 41.","journal-title":"Blood Cancer J"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11864-021-00841-4","article-title":"New treatment options for older patients with acute myeloid leukemia","volume":"22","author":"Saxena","year":"2021","unstructured":"Saxena K and Konopleva M. New treatment options for older patients with acute myeloid leukemia. Curr Treat Options Oncol 2021; 22: 39.","journal-title":"Curr Treat Options Oncol"},{"key":"ref5","unstructured":"World Health Organization. International classification of diseases: [9th] ninth revision, basic tabulation list with alphabetic index. World Health Organization; 1978."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D&#xF6","year":"2017","unstructured":"Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, Löwenberg B and Bloomfield CD. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017; 129: 424-447.","journal-title":"Blood"},{"key":"ref7","unstructured":"Chinese Society of Hematology, Chinese Medical Association; Chinese Medical Doctor Association, Hematology Branch. Chinese guidelines for the clinical application of antibacterial drugs for agranulocytosis with fever (2020). Zhonghua Xue Ye Xue Za Zhi 2020; 41: 969-978."},{"key":"ref8","unstructured":"Chinese Association Hematologists; Chinese Invasive Fungal Infection Working Group. [The Chinese guidelines for the diagnosis and treatment of invasive fungal disease in patients with hematological disorders and cancers (the 6th revision)]. Zhonghua Nei Ke Za Zhi 2020; 59: 754-763."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL and Angus DC. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016; 315: 801-810.","journal-title":"JAMA"},{"key":"ref10","unstructured":"Association Shock and Sepsis Society of the Chinese Research Hospital, Pla War Wound and Trauma Society of the Chinese People’s Liberation Army. Chinese expert consensus on diagnosis and treatment of traumatic multiple organ dysfunction syndrome. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2022; 34: 225-238."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13045-023-01424-6","article-title":"Recent advances in targeted therapies in acute myeloid leukemia","volume":"16","author":"RS","year":"2023","unstructured":"Bhansali RS, Pratz KW and Lai C. Recent advances in targeted therapies in acute myeloid leukemia. J Hematol Oncol 2023; 16: 29.","journal-title":"J Hematol Oncol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1097\/PPO.0000000000000567","article-title":"How we incorporate venetoclax in treatment regimens for acute myeloid leukemia","volume":"28","author":"Maiti","year":"2022","unstructured":"Maiti A and Konopleva MY. How we incorporate venetoclax in treatment regimens for acute myeloid leukemia. Cancer J 2022; 28: 2-13.","journal-title":"Cancer J"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Guarana M and Nucci M. Should patients with acute myeloid leukemia treated with venetoclax-based regimens receive antifungal prophylaxis? Leuk Res 2023; 131: 107341.","DOI":"10.1016\/j.leukres.2023.107341"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41408-022-00770-x","article-title":"Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis","volume":"12","author":"Kwag","year":"2022","unstructured":"Kwag D, Cho BS, Bang SY, Lee JH, Min GJ, Park SS, Park S, Yoon JH, Lee SE, Eom KS, Kim YJ, Lee S, Min CK, Cho SG, Lee JW and Kim HJ. Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis. Blood Cancer J 2022; 12: 169.","journal-title":"Blood Cancer J"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.2147\/IDR.S254478","article-title":"An overview of the management of the most important invasive fungal infections in patients with blood malignancies","volume":"13","author":"Shariati","year":"2020","unstructured":"Shariati A, Moradabadi A, Chegini Z, Khoshbayan A and Didehdar M. An overview of the management of the most important invasive fungal infections in patients with blood malignancies. Infect Drug Resist 2020; 13: 2329-2354.","journal-title":"Infect Drug Resist"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1093\/jac\/dkac190","article-title":"Safety and risk of febrile recurrence after early antibiotic discontinuation in high-risk neutropenic patients with haematological malignancies: a multicentre observational study","volume":"77","author":"Paret","year":"2022","unstructured":"Paret R, Le Bourgeois A, Guillerm G, Tessoulin B, Rezig S, Gastinne T, Couturier MA, Boutoille D, Lecomte R, Ader F, Le Gouill S, Ansart S, Talarmin JP and Gaborit B. Safety and risk of febrile recurrence after early antibiotic discontinuation in high-risk neutropenic patients with haematological malignancies: a multicentre observational study. J Antimicrob Chemother 2022; 77: 2546-2556.","journal-title":"J Antimicrob Chemother"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1080\/14787210.2020.1820863","article-title":"Management of fever and neutropenia in the adult patient with acute myeloid leukemia","volume":"19","author":"Peseski","year":"2021","unstructured":"Peseski AM, McClean M, Green SD, Beeler C and Konig H. Management of fever and neutropenia in the adult patient with acute myeloid leukemia. Expert Rev Anti Infect Ther 2021; 19: 359-378.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.3109\/10428194.2011.636812","article-title":"Infectious complications in adult acute myeloid leukemia: analysis of the Acute Leukemia French Association-9802 prospective multicenter clinical trial","volume":"53","author":"Cannas","year":"2012","unstructured":"Cannas G, Pautas C, Raffoux E, Quesnel B, de Botton S, de Revel T, Reman O, Gardin C, Elhamri M, Boissel N, Fenaux P, Michallet M, Castaigne S, Dombret H and Thomas X. Infectious complications in adult acute myeloid leukemia: analysis of the Acute Leukemia French Association-9802 prospective multicenter clinical trial. Leuk Lymphoma 2012; 53: 1068-1076.","journal-title":"Leuk Lymphoma"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"5494","DOI":"10.7150\/jca.50802","article-title":"A practical update on the epidemiology and risk factors for the emergence and mortality of bloodstream infections from real-world data of 3014 hematological malignancy patients receiving chemotherapy","volume":"12","author":"Chen","year":"2021","unstructured":"Chen S, Lin K, Li Q, Luo X, Xiao M, Chen M, Zhu H, Chen Y, Wu X, Zeng Y, Zhang Y, Ally IH, Xu J, Ren J, Chen Z, Hu J and Yang T. A practical update on the epidemiology and risk factors for the emergence and mortality of bloodstream infections from real-world data of 3014 hematological malignancy patients receiving chemotherapy. J Cancer 2021; 12: 5494-5505.","journal-title":"J Cancer"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Baier C, Linke L, Eder M, Schwab F, Chaberny IF, Vonberg RP and Ebadi E. Incidence, risk factors and healthcare costs of central line-associated nosocomial bloodstream infections in hematologic and oncologic patients. PLoS One 2020; 15: e0227772.","DOI":"10.1371\/journal.pone.0227772"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"7031","DOI":"10.1007\/s00520-022-07126-y","article-title":"A real-world study of infectious complications of venetoclax combined with decitabine or azacitidine in adult acute myeloid leukemia","volume":"30","author":"Zhu","year":"2022","unstructured":"Zhu LX, Chen RR, Wang LL, Sun JN, Zhou D, Li L, Qian JJ, Zhang Y, Tong HY, Yu WJ, Meng HT, Mai WY, Xie WZ, Jin J, Ye XJ and Zhu HH. A real-world study of infectious complications of venetoclax combined with decitabine or azacitidine in adult acute myeloid leukemia. Support Care Cancer 2022; 30: 7031-7038.","journal-title":"Support Care Cancer"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","article-title":"Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study","volume":"19","author":"DiNardo","year":"2018","unstructured":"DiNardo CD, Pratz KW, Letai A, Jonas BA, Wei AH, Thirman M, Arellano M, Frattini MG, Kantarjian H, Popovic R, Chyla B, Xu T, Dunbar M, Agarwal SK, Humerickhouse R, Mabry M, Potluri J, Konopleva M and Pollyea DA. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol 2018; 19: 216-228.","journal-title":"Lancet Oncol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/ajh.26061","article-title":"intensive chemotherapy in acute myeloid leukemia: a propensity score matched analysis stratified by risk of treatment-related mortality","volume":"96","author":"Maiti","year":"2021","unstructured":"Maiti A, Qiao W, Sasaki K, Ravandi F, Kadia TM, Jabbour EJ, Daver NG, Borthakur G, Garcia-Manero G, Pierce SA, Montalbano KS, Pemmaraju N, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Takahashi K, Yilmaz M, Jain N, Kornblau SM, Andreeff M, Bose P, Ferrajoli A, Issa GC, Masarova L, Thompson PA, Rausch CR, Ning J, Kantarjian HM, DiNardo CD and Konopleva MY. Venetoclax with decitabine vs. intensive chemotherapy in acute myeloid leukemia: a propensity score matched analysis stratified by risk of treatment-related mortality. Am J Hematol 2021; 96: 282-291.","journal-title":"Am J Hematol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","unstructured":"Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, McKeegan E, Salem AH, Zhu M, Ricker JL, Blum W, DiNardo CD, Kadia T, Dunbar M, Kirby R, Falotico N, Leverson J, Humerickhouse R, Mabry M, Stone R, Kantarjian H and Letai A. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov 2016; 6: 1106-1117.","journal-title":"Cancer Discov"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"5565","DOI":"10.1182\/bloodadvances.2021005538","article-title":"Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia","volume":"5","author":"Cherry","year":"2021","unstructured":"Cherry EM, Abbott D, Amaya M, McMahon C, Schwartz M, Rosser J, Sato A, Schowinsky J, Inguva A, Minhajuddin M, Pei S, Stevens B, Winters A, Jordan CT, Smith C, Gutman JA and Pollyea DA. Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia. Blood Adv 2021; 5: 5565-5573.","journal-title":"Blood Adv"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM and Konopleva MY. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol 2020; 7: e724-e736.","DOI":"10.1016\/S2352-3026(20)30210-6"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"584974","DOI":"10.3389\/fonc.2020.584974","article-title":"Targeting Bcl-2 proteins in acute myeloid leukemia","volume":"10","author":"Wei","year":"2020","unstructured":"Wei Y, Cao Y, Sun R, Cheng L, Xiong X, Jin X, He X, Lu W and Zhao M. Targeting Bcl-2 proteins in acute myeloid leukemia. Front Oncol 2020; 10: 584974.","journal-title":"Front Oncol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s00520-021-06471-8","article-title":"Induction therapy for acute lymphoblastic leukemia: incidence and risk factors for bloodstream infections","volume":"30","author":"RAM","year":"2022","unstructured":"Silva RAM, de Mendonça RMH, Dos Santos Aguiar S, Yajima JC, Marson FAL, Brandalise SR and Levy CE. Induction therapy for acute lymphoblastic leukemia: incidence and risk factors for bloodstream infections. Support Care Cancer 2022; 30: 695-702.","journal-title":"Support Care Cancer"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1046\/j.1365-2141.1999.01550.x","article-title":"The MCR Childhood Leukaemia Working Party","volume":"106","author":"Riley","year":"1999","unstructured":"Riley LC, Hann IM, Wheatley K and Stevens RF. Treatment-related deaths during induction and first remission of acute myeloid leukaemia in children treated on the Tenth Medical Research Council acute myeloid leukaemia trial (MRC AML10). The MCR Childhood Leukaemia Working Party. Br J Haematol 1999; 106: 436-444.","journal-title":"Br J Haematol"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Candoni A, Lazzarotto D, Papayannidis C, Piccini M, Nadali G, Dargenio M, Riva M, Fracchiolla N, Mellillo L, Dragonetti G, Del Principe MI, Cattaneo C, Stulle M, Pasciolla C, De Marchi R, Delia M, Tisi MC, Bonuomo V, Sciumè M, Spadea A, Sartor C, Griguolo D, Buzzatti E, Basilico CM, Sarlo C, Piccioni AL, Cerqui E, Lessi F, Olivieri A, Fanin R, Luppi M and Pagano L. Prospective multicenter study on infectious complications and clinical outcome of 230 unfit acute myeloid leukemia patients receiving first-line therapy with hypomethylating agents alone or in combination with Venetoclax. Am J Hematol 2023; 98: E80-E83.","DOI":"10.1002\/ajh.26846"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"107043","DOI":"10.1016\/j.leukres.2023.107043","article-title":"Incidence and predisposing factors of infection in patients treated with hypomethylating agents","volume":"127","author":"Kirkizlar","year":"2023","unstructured":"Kirkizlar TA, Kirkizlar O, Demirci U, Umut A, Iflazoglu H, Umit EG and Demir AM. Incidence and predisposing factors of infection in patients treated with hypomethylating agents. Leuk Res 2023; 127: 107043.","journal-title":"Leuk Res"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1182\/bloodadvances.2019000930","article-title":"Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents","volume":"3","author":"Aldoss","year":"2019","unstructured":"Aldoss I, Dadwal S, Zhang J, Tegtmeier B, Mei M, Arslan S, Al Malki MM, Salhotra A, Ali H, Aribi A, Sandhu K, Khaled S, Snyder D, Nakamura R, Stein AS, Forman SJ, Marcucci G and Pullarkat V. Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents. Blood Adv 2019; 3: 4043-4049.","journal-title":"Blood Adv"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1080\/10428194.2022.2047964","article-title":"Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax","volume":"63","author":"Chen","year":"2022","unstructured":"Chen EC, Liu Y, Harris CE, Winer ES, Wadleigh M, Lane AA, Vedula RS, Lindsley RC, Copson KM, Charles A, Marty F, Neuberg D, DeAngelo DJ, Stone RM, Luskin MR, Issa NC and Garcia JS. Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax. Leuk Lymphoma 2022; 63: 1934-1941.","journal-title":"Leuk Lymphoma"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","unstructured":"DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, Frankfurt O, Konopleva M, Wei AH, Kantarjian HM, Xu T, Hong WJ, Chyla B, Potluri J, Pollyea DA and Letai A. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 2019; 133: 7-17.","journal-title":"Blood"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1007\/s00432-022-03995-2","article-title":"Impact of treatment intensity on infectious complications in patients with acute myeloid leukemia","volume":"149","author":"Tober","year":"2023","unstructured":"Tober R, Schnetzke U, Fleischmann M, Yomade O, Schrenk K, Hammersen J, Glaser A, Thiede C, Hochhaus A and Scholl S. Impact of treatment intensity on infectious complications in patients with acute myeloid leukemia. J Cancer Res Clin Oncol 2023; 149: 1569-1583.","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["American Journal of Cancer Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajcr\/14\/12\/ajcr0160111.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:51:40Z","timestamp":1766022700000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajcr\/14\/12\/ajcr0160111.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":36,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.62347\/vzzv6163","relation":{},"ISSN":["2156-6976"],"issn-type":[{"value":"2156-6976","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]}}}